This study investigated whether patients with ischaemic retinal vasculitis have a worse visual outcome than those with non-ischaemic disease. A retrospective study was made of 53 patients with idiopathic retinal vasculitis (RV), with minimum 5 year follow-up. Patients were categorised into ischaemic and non-ischaemic groups by fluorescein angiography. Visual outcome was determined by visual acuity at their last attendance. Twenty patients (38 eyes) had ischaemic RV; 33 patients (63 eyes) had non-ischaemic RV. At presentation there was no significant difference between the groups in the proportion of eyes with poor vision (6/60 or less). Ischaemic RV patients had a worse visual outcome than those with non-ischaemic RV: 13 of 38 (34%) eyes in the ischaemic group had a final poor vision compared with 4 of 63 (6%) eyes in the non-ischaemic group (Fisher's exact test, p = 0.0005).
Aims-To determine whether urinary neopterin:creatinine (UNC) ratios relate to disease activity in idiopathic retinal vasculitis (RV). Methods-18 patients with RV were prospectively recruited into a year long longitudinal study. Patients collected first morning urine samples on a weekly basis and on the same day completed a diary which documented their subjective view of RV activity and any concurrent infection. They were examined in clinic on a 6-8 weekly basis and an objective assessment was made of RV disease activity. 14 healthy controls collected urine samples in the same way. Results-UNC ratios were significantly higher in patients than in controls (p=0.004, Mann-Whitney U test). UNC ratios were significantly higher when, according to their diaries, the patients had a subjective flare up of RV (p=0.001, Mann-Whitney U test). Subjective increased RV activity occurred more often when the patients had a concurrent infection (p<0.0001, 2 test). There was no significant diVerence in the UNC ratio between objective clinical relapse and non-relapse of RV. There was moderate agreement between the clinical assessment and patients' subjective impression of RV activity ( =0.48). Conclusions-Higher neopterin levels reflect cell mediated disease that occurs in RV, but UNC ratios are not recommended as a means of monitoring clinical disease activity in RV. (Br J Ophthalmol 2001;85:30-33)
Determination of serum phenytoin has been carried out at the State Hospital for Epileptics in collaboration with the Central Laboratory, Drammen Hospital, since July 1962. METHOD AND MATERIALThe applied technique has been described by Svensmark et al. (8). The main steps are the following:(1) Phenytoin (diphenylhydantoin) and barbiturates are extracted from serum with chloroform.(2) The barbiturates are extracted from the chloroform phase by a borate buffer (PH 9).(3) Phenytoin is subsequently extracted from the chloroform phase by a carbonate (4) Spectrophotometrical reading. During the first year 312 determinations were made in 180 patients, chiefly from the State Hospital for Epileptics and partly from the Diagnostic Station for Epilepsy, Department of Neurology, Rikshospitalet.As the patients at the State Hospital for Epileptics mainly constitute serious cases of the disease, phenytoin only rarely was used alone, but mostly together with a smaller dose of phenobarbital, this group comprising approximately half of the material (Table I).A number of patients treated with other drugs were also investigated in order to obtain a measure of the interference of these preparations upon the determination of serum phenytoin.A smaller group termed "irregular medication" consists of cases revealing exceptional low values of serum phenytoin as compared with the dose, and irregular intake being admitted by the patient upon inquiry. Fig. 1 shows the range of the dosage of phenytoin in mg/kg body weight, with a maximum at 5 mg/kg in the group treated with phenytoin and phenobarbital. buffer (pH 1 I).Epilepsia, 5 (1964) 364-370
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.